POZZI, Samantha
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.087
EU - Europa 5.481
AS - Asia 5.206
SA - Sud America 820
AF - Africa 187
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 7
Totale 24.820
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.888
GB - Regno Unito 2.065
SG - Singapore 1.532
CN - Cina 1.368
IT - Italia 929
HK - Hong Kong 654
BR - Brasile 596
VN - Vietnam 586
DE - Germania 525
SE - Svezia 452
FI - Finlandia 335
FR - Francia 253
UA - Ucraina 245
RU - Federazione Russa 230
TR - Turchia 169
IN - India 155
BD - Bangladesh 130
KR - Corea 124
CA - Canada 104
ID - Indonesia 93
BG - Bulgaria 87
AR - Argentina 71
IQ - Iraq 61
MA - Marocco 56
JP - Giappone 54
IE - Irlanda 50
NL - Olanda 47
MX - Messico 45
ZA - Sudafrica 42
ES - Italia 38
PH - Filippine 36
PL - Polonia 36
PK - Pakistan 34
EC - Ecuador 33
CO - Colombia 30
AE - Emirati Arabi Uniti 29
BE - Belgio 29
CL - Cile 25
LT - Lituania 24
AU - Australia 23
CZ - Repubblica Ceca 23
SA - Arabia Saudita 23
MY - Malesia 22
PY - Paraguay 19
EG - Egitto 18
UZ - Uzbekistan 17
VE - Venezuela 17
AT - Austria 15
CH - Svizzera 13
IR - Iran 13
CR - Costa Rica 12
DO - Repubblica Dominicana 12
NO - Norvegia 12
TN - Tunisia 12
JO - Giordania 11
UY - Uruguay 11
IL - Israele 10
KE - Kenya 10
PT - Portogallo 10
TW - Taiwan 10
AZ - Azerbaigian 9
HU - Ungheria 9
KG - Kirghizistan 9
PE - Perù 9
NZ - Nuova Zelanda 8
RO - Romania 8
TH - Thailandia 8
BO - Bolivia 7
BZ - Belize 7
DZ - Algeria 7
NG - Nigeria 7
DK - Danimarca 6
GH - Ghana 6
GR - Grecia 6
LB - Libano 6
NP - Nepal 6
TZ - Tanzania 6
BH - Bahrain 5
ET - Etiopia 5
KZ - Kazakistan 5
AL - Albania 4
BY - Bielorussia 4
CY - Cipro 4
EU - Europa 4
JM - Giamaica 4
KH - Cambogia 4
MD - Moldavia 4
OM - Oman 4
RS - Serbia 4
EE - Estonia 3
GP - Guadalupe 3
HR - Croazia 3
LV - Lettonia 3
PR - Porto Rico 3
QA - Qatar 3
SN - Senegal 3
UG - Uganda 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AO - Angola 2
Totale 24.778
Salva come PNG Salva come JPEG
Città #
Southend 1.620
Ashburn 1.353
Fairfield 1.270
Santa Clara 1.161
Singapore 1.005
Woodbridge 828
Chandler 644
Hong Kong 643
Houston 623
Ann Arbor 487
Seattle 469
Wilmington 455
San Jose 452
Cambridge 450
Jacksonville 418
Beijing 354
Dearborn 320
Nyköping 307
Hefei 292
London 258
Helsinki 242
Council Bluffs 219
Chicago 216
Los Angeles 214
New York 207
Ho Chi Minh City 196
Modena 180
Frankfurt am Main 144
The Dalles 139
Hanoi 138
San Diego 132
Seoul 112
Princeton 96
Milan 91
Salt Lake City 89
Sofia 84
Izmir 81
Eugene 79
Moscow 76
Shanghai 76
Buffalo 74
Munich 73
Lauterbourg 67
Rome 64
Jakarta 63
São Paulo 60
Dublin 48
Bremen 46
Casablanca 45
Dallas 43
Elk Grove Village 42
Redwood City 42
Columbus 39
Falls Church 38
Des Moines 36
Phoenix 36
Fremont 33
Tokyo 33
Orem 32
Tampa 29
Warsaw 29
Da Nang 28
Guangzhou 28
San Francisco 28
San Giuliano Milanese 28
Chennai 26
Atlanta 25
Boardman 25
Montreal 25
Toronto 24
Turku 24
Brussels 23
Baghdad 21
Norwalk 21
Bologna 19
Brooklyn 19
Denver 19
Lancaster 19
Miami 19
Belo Horizonte 18
Dong Ket 18
Haiphong 18
Rio de Janeiro 18
Sterling 18
Amsterdam 17
Johannesburg 17
Nanjing 17
Poplar 16
Boston 15
Buenos Aires 15
Dhaka 15
Manchester 15
Nuremberg 15
Ottawa 15
Paris 15
Parma 15
Quito 15
Stockholm 15
Charlotte 14
Detroit 14
Totale 17.948
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 618
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 606
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 523
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 516
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 489
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 443
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 439
The undergraduate nursing student evaluation of clinical learning environment: an Italian survey [La valutazione dell'ambiente di apprendimento clinico da parte degli studenti del Corso di Laurea in Infermieristica: una indagine italiana] 436
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 405
Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report 403
Cell-penetrating CaCO3nanocrystals for improved transport of NVP-BEZ235 across membrane barrier in T-cell lymphoma 387
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) 383
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 381
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 381
Activity of BKM120 and BEZ235 against lymphoma cells 369
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 368
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 363
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 362
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 347
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 340
A concise review of lenalidomide therapy for follicular lymphoma 340
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 335
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 333
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells 332
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 323
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 315
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 314
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 313
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 307
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 306
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 303
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 299
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 299
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 296
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 292
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 285
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases 284
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 275
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 275
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 275
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 274
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 274
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 273
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 272
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. 268
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 264
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 264
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. 260
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease 252
A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma 247
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 246
Low-molecular-weight heparin for vertebral artery dissection 243
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 240
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 235
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo 234
Bortezomib and plasma cell leukemia 233
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 233
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 228
The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease 222
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 222
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma 219
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 218
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts 218
Diffuse B-large cell lymphomas with hepatitis C virus (HCV) infection: An interim report of a comparative study with or without antiviral treatment after chemotherapy 217
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. 210
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 210
The role of bisphosphonates in multiple myeloma: Mechanisms, side effects, and the future 209
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. 199
AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3 beta 198
Antiviral treatment with interferon +/- ribavirin after chemotherapy for diffuse large B-cell non-Hodgkin lymphomas with hepatitis C virus (HCV) infection 198
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. 198
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED FOLLICULAR LYMPHOMAS: LOW TOXICITY AND EXTENDED PROGRESSION FREE SURVIVAL. R1235 Barcelona, Spain. Bone Marrow Transplantation March 2004, Volume 33, Supplement 1 196
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice 186
Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma 179
Role of thalidomide in previously untreated patients with multiple myeloma 178
Bisphosphonates and Atypical Femoral Fractures 176
A simple and safe nomogram for the management of oral anticoagulation prior to minor surgery 174
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis 170
Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas 168
From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights 165
Fatty acid synthase is a novel therapeutic target in multiple myeloma. 156
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity 144
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study 141
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature 130
Clinical trials of bisphosphonates in multiple myeloma 124
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 124
Management of adverse events and supportive therapy in relapsed/refractory multiple myeloma 113
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3Β activation and RNA polymerase II inhibition 110
Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: Pathophysiology, clinical presentation, and treatment 110
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study) 108
Autologous stem cell transplantation for newly diagnosed follicular lymphomas: low toxicity and extended progression free survival 99
Primary cardiac lymphoma: A case report and review 67
A new digital droplet PCR method for looking at epigenetics in diffuse large B‐cell lymphomas: The role of BMI1, EZH2, and USP22 genes 33
Totale 24.989
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.052
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.052
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021144 0 0 0 0 0 0 0 0 0 0 0 144
2021/20221.758 77 166 203 63 40 153 100 95 193 148 314 206
2022/20231.821 197 221 163 192 189 263 44 157 250 14 79 52
2023/20241.410 74 77 70 155 322 98 200 160 23 32 70 129
2024/20253.793 123 50 88 270 819 610 288 195 398 171 332 449
2025/20267.692 431 297 563 962 1.221 617 919 447 800 725 591 119
Totale 24.989